37 results about "Antigen Targeting" patented technology

The application provides an autoantibody marker for predicting the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, a series of autoantibody marker molecules are screened by detecting autoantibodies against different antigen targets in blood of lung cancer patients in the third stage, and the autoantibody marker molecules have great correlation with the prediction of the effect of lung cancer immunneoadjuvant therapy, and three autoantibody biomarkers with better prediction of the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage are further screened by combining with a CART decision tree strategy; the combination of the autoantibody biomarkers can be used for efficiently predicting whether the lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage is effective, providing a reference basis for a clinician to decide a treatment scheme, providing a new prediction means for the effect of lung cancer immunneoadjuvant therapy on lung cancer patients in the third stage, and having important scientific significance and clinical application value.

Provided are compositions and methods for treating Lewis Y antigen positive cancers in mammalian subjects by administering an effective amount of a radionuclide-labeled Lewis Y antigen targeting agent such as an antibody labeled with an alpha particle-emitting radionuclide such as 225Ac. The methods may further include administration of additional agents, such as radiosensitizing agents, immune checkpoint therapies, CD47 blockades, and / or DNA damage response inhibitors.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

This invention relates to recombinant mammalian cells and their use in treating cancer. The present invention specifically relates to the co-expression of an adapter CAR and a conventional CAR in CAR T cells and the use of these cells in treating lymphoma. The invention also relates to pharmaceutical compositions comprising such recombinant mammalian cells, as well as their uses in cancer therapy.

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

The present invention relates to a dual antigen-targeting protein complex comprising an antibody or its antigen-binding fragment and an affibody. More specifically, the dual antigen-targeting protein complex comprises an EGFR (Epidermal Growth Factor Receptor) or PSMA (Prostate Specific Membrane Antigen) target site containing an antibody or its antigen-binding fragment, and a CD137 target site containing an affibody bound to the antibody or its antigen-binding fragment. When the dual antigen-targeting protein complex or a composition containing it is used, cancer can be effectively prevented or treated.

Anti-EphA2 antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise a Bcl-xL inhibitor drug moiety and an anti-EphA2 antibody or antigen-binding fragment thereof that binds the antigen target, e.g., the antigen expressed on a tumor or other cancer cells. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making the same are also disclosed.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The invention discloses a colloidal gold immunochromatography test strip for saliva sample detection and a preparation method thereof.The test strip comprises a supporting layer, and a sample pad, a combination pad, an NC membrane and a water absorption layer are sequentially arranged on the supporting layer from the sample introduction end; at least partial areas of the sample pad and the combination pad are obtained by drying after being pretreated by saliva sample treatment liquid, and the saliva sample treatment liquid comprises the following components: a zwitterionic anti-adsorption buffer system, an antibody conformation relaxation agent, a chelating agent type colloid redispersant, hydrophilic small molecular protein and a cyclodextrin type hydrophobic shielding agent. According to the method, systematic improvement is performed from the biochemical performance of the sample and the state of the antigen target, so that the defects that the target is covered by the colloidal environment of saliva and the target is lost due to aggregation of the target antigen are effectively overcome, and the detection sensitivity is greatly improved.

The application discloses an antibody conjugated drug binding prediction method based on a virtual graph and multi-scale features, proposes a drug carrier, a linker, an antibody heavy chain and a light chain, and an antigen target protein initial feature construction method, proposes a 1DCNN for extracting drug sequence features, designs a drug feature extraction method based on a graph virtual node, introduces a virtual node and a virtual edge into a molecular structure graph, takes a Graph Transformer as a graph feature extractor, takes a virtual node feature as a drug representation, then inputs protein and drug features into a feature fusion module, adds an attention mechanism and a gated skip connection mechanism in feature fusion, captures potential interactions while fusing feature information of different hidden layers, and realizes higher precision affinity prediction. The application can solve the technical problems that existing methods are difficult to extract structural features of antibody conjugated drugs and features of different components are difficult to fuse.

The invention discloses an oral vaccine as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations. The oral vaccine comprises a core, and a permeation enhancing layer, an active molecular layer and an enteric coating layer which are sequentially coated on the surface of the core, the core is a biodegradable polymer nano particle; the permeation enhancing layer is a polydopamine layer loaded with a permeation enhancer; the active molecular layer is a chitosan layer loaded with an antigen and a targeting substance. The oral vaccine provided by the embodiment of the invention is good in stability, can ensure that the antigen is stable in gastrointestinal tracts and keeps activity, realizes targeted release of intestinal tracts, can activate far-end mucous membrane tissues at the same time, realizes broad-spectrum IgA and IgG immunization, and is suitable for delivery of various oral antigens.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.

The present disclosure relates to combinations of tumor-targeted IL2 receptor agonists and multispecific T-cell engagers, e.g., for use in stimulating T-cells against cancer cells or treatment of cancer. The tumor-targeted IL2 receptor agonists comprise a tumor-associated antigen targeting moiety and an IL2 moiety. The multispecific T-cell engagers comprise a tumor-associated antigen targeting moiety and a T-cell receptor complex targeting moiety.

This invention discloses a method for preparing a nanozyme-antibody complex based on site-directed enzyme catalytic coupling, its products, and applications, belonging to the field of nanomedicine technology. The preparation method of this invention involves the site-directed introduction of an azide group at the Fc segment of the antibody's glycan chain through a cascade catalysis of N-glycosidase (PNGase F) and transglutaminase (TGase). Then, a click chemistry reaction is carried out between a platinum nanozyme modified with a DBCO group and the azide group, thereby constructing a nanozyme-antibody conjugate complex consisting of a single antibody coupled with two platinum nanozymes. During the coupling process, the structural integrity of the antibody and its antigen-targeting recognition function are maintained to the greatest extent, and the complex possesses highly efficient enzyme-like catalytic activity and good environmental stability, significantly improving the efficiency of converting the concentration information of the target substance into a color signal.

Provided herein are solid tumor antigen targets for chimeric receptors and chimeric inhibitory receptors. The chimeric antigen receptors (CARs) described herein include a first antigen-binding domain that binds a first antigen; a second extracellular antigen-binding domain; a transmembrane domain; and one or more intracellular signaling domains. The disclosure also provides methods of using the same, such as for the treatment of cancer.

The invention belongs to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and particularly relates to a glutamic acid-ureido-lysine compound containing an L-proline derivative as well as a preparation method and application of the glutamic acid-ureido-lysine compound. A radioactive preparation obtained by labeling the glutamic acid-ureido-lysine compound containing the L-proline derivative with radionuclide can be specifically combined with a prostate specific membrane antigen target spot, has high uptake at a tumor site with high expression of a prostate specific membrane antigen, has a good tumor / non-target ratio, and can be used for preparing a prostate specific membrane antigen. The medicine is a novel tumor radiopharmaceutical with popularization and application values.

The present invention relates to a modified immune cell for use in the treatment of a solid tumor in a subject wherein the modified immune cell comprises one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancer cell of said solid tumor, in said immune cell, nuclear receptor subfamily group 2 F member 6 (NR2F6) activity is suppressed (as compared to a control immune cell), and binding of the immune cell to an antigen is associated with death of the cancer cell expressing the antigen, and inducing a secondary immune response against a cancer cell of a solid tumor in a subject, the secondary immune response is non-specific (epitope diffusion) for the antigen targeted to the transgenic construct. The present invention also relates to a modified immune cell comprising one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancer cell of a solid tumor in which NR2F6 activity and Casite B line lymphoma oncogene-b (CBLB) activity are inhibited (as compared to a control immune cell). The invention also relates to pharmaceutical compositions comprising a modified immune cell suitable for the treatment of solid tumors, additionally comprising a pharmaceutically acceptable carrier, and to in vitro methods for enhancing the cytolytic activity of the modified immune cell.

Lymphocytes having a suppressed autophagy gene useful in immunotherapy are disclosed. The lymphocytes can express an antigen targeting receptor such as a chimeric antigen receptor (CAR) or endogenous or engineered T-cell receptor to target cells expressing a tumor-specific antigen. Methods of making and using such lymphocytes are disclosed. Some such lymphocytes are useful in conducting CAR-T or TCR-T therapy.

The invention discloses a TCR (T cell receptor) targeting to MAGEA1 and application of the TCR. The invention provides a brand new TCR sequence of a high-affinity and high-specificity targeting MAGEA1 antigen, which is beneficial to development of drugs targeting MAGEA1 positive tumors, improves the treatment effect and safety of TCR-T cell therapy, and provides an innovative sequence resource for clinical transformation in the field of tumor immunotherapy.

The invention relates to the field of biotechnology and cell therapy, in particular to a recombinant construct, a CAR (chimeric antigen receptor) modified cell and application. On the objective basis of different antigen target spots, such as CD19, CLDN18.2 or BCMA and other different antigen target spots corresponding to abnormal expression of tumors, the target spots are used as target spots for clinical treatment; under the condition that the expression of the chimeric antigen is not changed, two cell factors are secreted synergistically; the long-term treatment effect of immune cells is enhanced, and meanwhile, the treatment risk is reduced.

Disclosed is a method of producing a cell population containing immune cells expressing a chimeric antigen receptor (CAR), the method comprising co-culturing CAR-expressing immune cells and target antigen-expressing cells, the CAR-expressing immune cells being cells in which a CAR gene has been introduced and the target antigen-expressing cells expressing a gene for an antigen targeted by the CAR.

The application relates to a chimeric antigen receptor that directly and / or indirectly targets cells and their uses in tumor immunotherapy. The application also relates to polynucleotides that encode the chimeric antigen receptor and optionally accessory genes, vectors, and host cells comprising the chimeric antigen receptor and optionally a second antigen targeting moiety (e.g., a second chimeric antigen receptor or a bispecific molecule). The application also relates to methods for preparing host cells comprising the chimeric antigen receptor and optionally the second antigen targeting moiety.

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular aspects relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of use of multispecific molecules in antigen-specific T cell activation, in inducing an antigen-specific immune response, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells that express the multispecific molecules, and methods of producing the multispecific molecules.

The invention relates to the technical field of IgY antibodies, in particular to a preparation method and application of an anti-human papilloma virus IgY antibody, and the preparation method comprises the following steps: S1, preparing an immunogen; s2, carrying out stepped immunization; s3, collection and pretreatment of hyper-immune eggs: from 18-25 days after primary immunization, collecting eggs laid by the immunized hens, and after surface disinfection, taking yolk liquid for later use; s4, preliminarily extracting an antibody; s5, preliminarily concentrating and purifying the antibody; s6, fine purification of the antibody; s7, performing preparation treatment on the antibody; according to the present invention, the HPV L1 virus-like particle (VLP) immunogen strategy is adopted, the cross protection potential of the high immunogenicity of the L1 VLP is completely performed, the efficient adjuvant system is matched, the poultry is effectively induced to produce the high titer neutralizing antibody with wide cross reactivity, and the defects of limited single antigen targeting type and narrow protection range are overcome.

Provided is an engineered cell expressing truly epitope-receptive MHC ectodomains, comprising a human leukocyte antigen molecule (HLA molecule), wherein the HLA molecule comprises a first chain and a second chain, wherein the first chain of the HLA molecule is selected from HLA-I heavy chains or HLA-II alpha chains, the second chain of the HLA molecule is selected from HLA-I light chains or HLA-II beta chains, and the first and second chains of the HLA molecule are non-covalently linked to form an HLA molecule with native HLA molecular functions. The engineered cells can be used for rapid identification and characterization of MHC restricted antigen peptides, and can efficiently and accurately develop and validate HLA neoantigen targeting immunotherapeutic biologics and drug candidates.

A trifunctional fusion protein for antigen targeting, anti-CD16A and immune effector cell activation is disclosed, which includes a CD16A binding region that specifically binds to CD16A, a TAA binding region that specifically binds to a tumor-associated antigen (TAA), an IL-15 / IL-15Rα complex formed by the binding of IL-15 to IL-15Rα, and an Fc domain. The designed tumor-targeting innate immune cell activation molecule is a trifunctional fusion protein of anti-TAA, anti-CD16A and the cytokine IL15, which targets NK cells to tumors by simultaneously binding to tumor-associated antigens (TAA) on tumor cells and CD16A on NK cells, and the NK cells release perforin and granzymes, causing apoptosis and tumor cell death. The cytokine IL15 expands and maintains the function of NK cells, stimulates the proliferation of immune cells and changes the immune microenvironment of tumors.

The invention discloses a multi-gene mutation tumor new antigen polypeptide algorithm, the specific sites of the mutated antigen targets are genes APRT p.E141V, KCTD10 p.Y172N, PABPC1 p.L218V, ADAM28 p.C315G, ARF3 p.G6V, KLHL2 p.E88G, CNOT11 p.S148R, C5orf42 p.Q1002L, ABLIM1 p.C190Y, BCLAF1 p.N629S, PABPC1 p.K312RfsTer10 and KRAS p.G12D, the 12 gene mutations cover hotspot mutation, low-frequency mutation and rare mutation, and the antigen polypeptide can be synthesized on a large scale and is used for subsequent PABPC1 p.L218V and a more effective personalized treatment scheme can be established for the patient.

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and / or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.

The invention belongs to biological medicines, and discloses an enhanced exosome for expressing an antigen-targeted antibody as well as a preparation method and application of the enhanced exosome. An antigen targeting antibody is expressed on the surface of the exosome, and the antigen targeting antibody comprises: 1) a signal peptide; (2) a histidine tag (His-tag) and a Flag tag; 3) a single-chain antibody region of a targeted antigen; 4) a hinge area; 5) transmembrane area; and 6) a fluorescent protein. The enhanced exosome is prepared by a gene engineering method, and surface modification of the exosome is realized by utilizing a lentiviral vector, so that the enhanced exosome has definite antigen targeting property and preparation sustainability.